Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Bedaquiline (as part of longer regimens)
Treatment for Extensively drug-resistant tuberculosis
Typical Dosage: 400mg daily for 2 weeks, then 200mg three times a week for 22 weeks
Effectiveness
80%
Safety Score
50%
Clinical Trials
25
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
400mg daily for 2 weeks, then 200mg three times a week for 22 weeks
Time to Effect
3-6 months
Treatment Duration
6 months (within 18-24 month regimen)
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$4,000
Monitoring:$2,000
Side Effect Mgmt:$1,000
Total Annual:$7,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$20,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$9,333
Cost per Remission
$9,333
Comparison vs Older XDR-TB regimens without Bedaquiline
Cost Difference
$-5,000/year
Less expensive
QALY Difference
+0.75 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Bedaquiline (as part of longer regimens) Outcomes
for Extensively drug-resistant tuberculosis
Efficacy Outcomes
Overall Effectiveness
+80%
Response Rate
+75%
Remission Rate
+75%
Common Side Effects
QT prolongation
+15%
Nausea
+18%
Arthralgia
+12%
Hepatotoxicity
+7%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov